These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 31084442)
21. Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran. Rezaee M; Izadi S; Keshavarz K; Borhanihaghighi A; Ravangard R J Med Econ; 2019 Apr; 22(4):297-305. PubMed ID: 30561242 [TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia. Alsaqa'aby MF; Vaidya V; Khreis N; Khairallah TA; Al-Jedai AH Ann Saudi Med; 2017; 37(6):433-443. PubMed ID: 29229891 [TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of the SLIMMER diabetes prevention intervention in Dutch primary health care: economic evaluation from a randomised controlled trial. Duijzer G; Bukman AJ; Meints-Groenveld A; Haveman-Nies A; Jansen SC; Heinrich J; Hiddink GJ; Feskens EJM; de Wit GA BMC Health Serv Res; 2019 Nov; 19(1):824. PubMed ID: 31711499 [TBL] [Abstract][Full Text] [Related]
24. Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands. Michels RE; de Fransesco M; Mahajan K; Hengstman GJD; Schiffers KMH; Budhia S; Harty G; Krol M Appl Health Econ Health Policy; 2019 Dec; 17(6):857-873. PubMed ID: 31444659 [TBL] [Abstract][Full Text] [Related]
25. A guided and unguided internet- and mobile-based intervention for chronic pain: health economic evaluation alongside a randomised controlled trial. Paganini S; Lin J; Kählke F; Buntrock C; Leiding D; Ebert DD; Baumeister H BMJ Open; 2019 Apr; 9(4):e023390. PubMed ID: 30967405 [TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison. Taheri S; Sahraian MA; Yousefi N J Med Econ; 2019 Jan; 22(1):71-84. PubMed ID: 30380350 [TBL] [Abstract][Full Text] [Related]
27. Complaint-Directed Mini-Interventions for Depressive Symptoms: A Health Economic Evaluation of Unguided Web-Based Self-Help Interventions Based on a Randomized Controlled Trial. Wijnen BF; Lokman S; Leone S; Evers SM; Smit F J Med Internet Res; 2018 Oct; 20(10):e10455. PubMed ID: 30274958 [TBL] [Abstract][Full Text] [Related]
28. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis. Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540 [TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States. Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273 [TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis. Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659 [TBL] [Abstract][Full Text] [Related]
32. Long-term efficacy and cost-effectiveness of blended cognitive behavior therapy for high fear of recurrence in breast, prostate and colorectal Cancer survivors: follow-up of the SWORD randomized controlled trial. Burm R; Thewes B; Rodwell L; Kievit W; Speckens A; van de Wal M; Prins J BMC Cancer; 2019 May; 19(1):462. PubMed ID: 31096934 [TBL] [Abstract][Full Text] [Related]
33. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208 [TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness of Therapist-Guided Internet-Based Cognitive Behavioral Therapy for Stress-Related Disorders: Secondary Analysis of a Randomized Controlled Trial. Lindsäter E; Axelsson E; Salomonsson S; Santoft F; Ljótsson B; Åkerstedt T; Lekander M; Hedman-Lagerlöf E J Med Internet Res; 2019 Sep; 21(9):e14675. PubMed ID: 31586370 [TBL] [Abstract][Full Text] [Related]
35. Economic evaluation of a guided and unguided internet-based CBT intervention for major depression: Results from a multi-center, three-armed randomized controlled trial conducted in primary care. Romero-Sanchiz P; Nogueira-Arjona R; García-Ruiz A; Luciano JV; García Campayo J; Gili M; Botella C; Baños R; Castro A; López-Del-Hoyo Y; Pérez Ara MÁ; Modrego-Alarcón M; Mayoral Cleríes F PLoS One; 2017; 12(2):e0172741. PubMed ID: 28241025 [TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness of Group and Internet Cognitive Behavioral Therapy for Insomnia in Adolescents: Results from a Randomized Controlled Trial. De Bruin EJ; van Steensel FJ; Meijer AM Sleep; 2016 Aug; 39(8):1571-81. PubMed ID: 27306272 [TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of combined cognitive and vocational rehabilitation in patients with mild-to-moderate TBI: results from a randomized controlled trial. Howe EI; Andelic N; Fure SCR; Røe C; Søberg HL; Hellstrøm T; Spjelkavik Ø; Enehaug H; Lu J; Ugelstad H; Løvstad M; Aas E BMC Health Serv Res; 2022 Feb; 22(1):185. PubMed ID: 35151285 [TBL] [Abstract][Full Text] [Related]
38. Early neurologically focused follow-up after cardiac arrest is cost-effective: A trial-based economic evaluation. Moulaert VR; Goossens M; Heijnders IL; Verbunt JA; Heugten CM Resuscitation; 2016 Sep; 106():30-6. PubMed ID: 27350371 [TBL] [Abstract][Full Text] [Related]
39. Modeled cost-effectiveness of transforaminal lumbar interbody fusion compared with posterolateral fusion for spondylolisthesis using N(2)QOD data. Carreon LY; Glassman SD; Ghogawala Z; Mummaneni PV; McGirt MJ; Asher AL J Neurosurg Spine; 2016 Jun; 24(6):916-21. PubMed ID: 26895529 [TBL] [Abstract][Full Text] [Related]
40. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis. Earnshaw SR; Graham J; Oleen-Burkey M; Castelli-Haley J; Johnson K Appl Health Econ Health Policy; 2009; 7(2):91-108. PubMed ID: 19731967 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]